Catalent Inc
NYSE:CTLT
Catalent Inc
Accounts Receivables
Catalent Inc
Accounts Receivables Peer Comparison
Competitive Accounts Receivables Analysis
Latest Figures & CAGR of Competitors
Company | Accounts Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Catalent Inc
NYSE:CTLT
|
Accounts Receivables
$1.3B
|
CAGR 3-Years
10%
|
CAGR 5-Years
18%
|
CAGR 10-Years
15%
|
|
Johnson & Johnson
NYSE:JNJ
|
Accounts Receivables
$14.9B
|
CAGR 3-Years
0%
|
CAGR 5-Years
1%
|
CAGR 10-Years
2%
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Accounts Receivables
$9.2B
|
CAGR 3-Years
9%
|
CAGR 5-Years
15%
|
CAGR 10-Years
18%
|
|
Pfizer Inc
NYSE:PFE
|
Accounts Receivables
$11B
|
CAGR 3-Years
4%
|
CAGR 5-Years
3%
|
CAGR 10-Years
2%
|
|
Merck & Co Inc
NYSE:MRK
|
Accounts Receivables
$11.4B
|
CAGR 3-Years
11%
|
CAGR 5-Years
8%
|
CAGR 10-Years
5%
|
|
Eli Lilly and Co
NYSE:LLY
|
Accounts Receivables
$7.9B
|
CAGR 3-Years
12%
|
CAGR 5-Years
9%
|
CAGR 10-Years
10%
|
See Also
What is Catalent Inc's Accounts Receivables?
Accounts Receivables
1.3B
USD
Based on the financial report for Mar 31, 2024, Catalent Inc's Accounts Receivables amounts to 1.3B USD.
What is Catalent Inc's Accounts Receivables growth rate?
Accounts Receivables CAGR 10Y
15%
Over the last year, the Accounts Receivables growth was -12%. The average annual Accounts Receivables growth rates for Catalent Inc have been 10% over the past three years , 18% over the past five years , and 15% over the past ten years .